Apta 20main 20image
Apta biosciences 20logo

Apta Biosciences Ltd

Beyond antibodies: solving unmet medical needs with advanced affinity technology

  • Stage Product In Development
  • Industry Biotechnology
  • Location London, United Kingdom
  • Currency GBP
  • Founded August 2013
  • Employees 15
  • Incorporation Type Other
  • Website aptabiosciences.com

Company Summary

Apta Biosciences Ltd is bringing to market a pipeline of game changing healthcare products using its proprietary third generation affinity molecules - “Seligos.” Apta is led by a team experienced in building life science companies from early stage to exit, having realized billions $ of value for investors. Apta plans to launch its first product in early H2 2017, with other products to follow.


  • A49f4703 3984 49c2 968f 29e07165959c
    Founder / Executive Chairman

    Experienced Life Science entrepreneur, executive & Board member. Recently exited medical device company "Phagenesis Ltd" to Nestle Health Sciences (strong returns to all shareholders), where he was a key member of the management team and Board. Fred is also a founder and Exec Director of Solus Scientific, which he has built to profitability and strong growth.

    Director of Anglo Scientific; MBA London Business School; Harvard undergraduate

  • 6fead616 750e 4ee8 9dce 60c9f6a9c50e
    Founder / Executive Director

    A Director of Anglo Scientific, Will has founded and led the growth of numerous early stage technology businesses where he has had operational and Board roles (including in vitro diagnostics). He is also an adviser to the Singapore government for new medical technologies.

    Prior to becoming an entrepreneur, Will worked in M&A at Lehman Brothers, Barclays Capital and JP Morgan

  • Default avatar
    Dr Alex Wilson
    Managing Director (Apta Singapore)

    Alex joined Apta from Maccine, a Contract Research Organisation for large pharma, where he spent 7 years, most recently as CEO (formerly COO and CSO). Prior to Maccine, he was with GlaxoSmithKline (UK & Singapore) for 9 years as a principal scientist & investigator.

  • Default avatar
    Dr Russ Medford
    Executive Committee

    Previously co-founder, CEO & President of AtheroGenics (IPO on NASDAQ); Founding Director, Inhibitex, (IPO on NASDAQ and subsequently sold to Bristol Myers for $2.5bn); Boards of numerous other biotech companies inlcuding Transcardiac Therapeutics, Somatocor, EmTech Bio; past Chairman Georgia Bio & Board of US Biotech Industry Association

  • 46824c60 682b 46d7 956b 1d3ff970ccd7
    Executive Committee

    Prof. Hematology & Oncology at Emory University; Ex President of the Federation of American Societies for Experimental Biology and Deputy National Vice President for Research of the American Cancer Society.

  • Default avatar
    Prof Teo Forcht-Dagi
    Executive Committee / Director

    Neurosurgeon and Prof. at Harvard Medical and Queens University Belfast. $10bn of value realization from commercializing early stage biotechnology and medical devices as a venture capitalist. Ex Chair of Scientific Advisory Boards for Lundbeck, Dupont & RBC. Advisor to the US FDA.

  • Default avatar
    Kenneth Moch
    Executive Committee

    Former President & CEO of Chimerix (NASDAQ:CMRX), BioMedical Enterprises, Alteon and Biocyte Corp; Co-founder & VP at The Liposome Company; 10+ years on the Board of BIO & Secretary of BIO’s Emerging Companies Section

Previous Investors

  • Default avatar
    Ranworth Capital